Report: Current Stock Reports

Dosing of the first patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
September 19, 2024

Continuation of the development of PRMT5 program
September 11, 2024

Fulfillment of conditions for the disbursement of the Tranche C of financing from the European Investment Bank
August 29, 2024

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 27th, 2024
June 27, 2024

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
June 27, 2024

Fulfillment of conditions for the disbursement of the Tranche B of financing from the European Investment Bank
June 19, 2024

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
June 14, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
June 14, 2024

Conclusion of funding agreement with the Polish Agency for Enterprise Development
June 4, 2024

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
May 29, 2024

Obtaining the status of Associate Partner within IPCEI Med4Cure
May 29, 2024

Conclusion of funding agreement with the National Centre for Research and Development
May 28, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
May 23, 2024

Preclinical and clinical data on RVU120 to be presented at the 2024 European Hematology Association Congress
May 14, 2024

Posters on preclinical data on RVU120 and Synthetic Lethality Programs presented at the 2024 AACR Annual Meeting
April 10, 2024

Conclusion of an agreement in the area of operational execution of RVU120 Phase II clinical trial in myelofibrosis
March 29, 2024

Ryvu project recommended for funding by the Polish Agency for Enterprise Development
March 27, 2024

Correction of the current report No. 12/2024 of March 6, 2024 – correction of obvious typographical error
March 8, 2024

Fulfillment of conditions for the disbursement of the Tranche A of financing from the European Investment Bank
March 6, 2024

Preclinical data on RVU120 and Synthetic Lethality Programs to be presented at the 2024 AACR Annual Meeting
March 6, 2024